Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Harry Lewis who wrote (281)	3/7/1998 7:35:00 PM
From: Michael Anthony	Read Replies (2) \| Respond to of 1321

Anyone been hearing about the new peptide vaccine? It is basically a re-engineered version of the patient's cancer which makes it recognizable to the bodies immune system. It is re-injected into the patient and the body then fights the cancer. The basically biopsy the cancer, rearrange it's peptide chain to make it recognizable as an antigen and then the body actually then recognizes the present cancer as a danger and attacks it. Tumors are vanishing left and right on many patients. All the research is just beginning, but I was impressed by what I saw. (was on TLC the other night) I just thought it might be competition for other companies such as this one regarding cancer treatment. QLT's attack on cancer involves basically tagging the cancer with a drug to make it recognizable for destruction by laser. The peptide vaccine works to make the body fight it's own battle. Anyone know anything more about it? I thought QLT had a unique approach, but this other seems quite impressive.

To: Harry Lewis who wrote (281)	3/8/1998 9:12:00 AM
From: Chris D	Read Replies (1) \| Respond to of 1321

Her $45.00 12-month target price is based on: A) upcoming expected FDA final approval for the use of Photofrin in the treatment of early lung cancer. B) Photofrin's German & French launch + other European filings with planned approvals in 1998. C) Phase III BPD for AMD trial completing enrollment on time. D) QLT is/was trading at a 27% discount (Dec. 12 - $16.70) to other photodynamic therapy companies despite being more advanced and having a stronger financial position. E) Most of the market valuation for QLT lies in the more attractive AMD market. Chris